Nexien BioPharma Inc. (NXEN): Is This Cannabinoid Stock a Hidden Gem or a Risky Bet?

Nexien BioPharma Inc. (OTC: NXEN) is a U.S.-based pharmaceutical company focused on developing cannabinoid-based treatments within FDA-compliant pathways. Formerly known as Intiva BioPharma, the company aims to harness cannabis-derived compounds for medical applications.

But with financial instability and halted R&D, does Nexien still have a future, or is it on the verge of collapse? Let’s break it down.

Nexien BioPharma Stock Price Today

  • Current Price: $0.0140 (as of March 3, 2025)
  • 52-Week Range: $0.0041 – $0.0495
  • Year-to-Date Performance: Up 150% from its January 2025 low of $0.0056

Despite its gains, Nexien remains a highly speculative stock with low liquidity and extreme volatility. Investors should approach with caution.

Financial Status: Running on Fumes?

  • Working Capital Deficit: $422,691 (as of Dec. 31, 2024)
  • Cash Reserves: $1,306 (yes, you read that right)
  • Debt & Liabilities: Mounting, with no clear revenue stream

Due to these financial struggles, Nexien paused all R&D activities and is now looking for potential mergers or restructuring opportunities to stay afloat.

Leadership Team: Who’s Steering the Ship?

  • Richard S. Greenberg (CEO & Chairman) – Formerly involved with Kanativa, Inc. and Israel Plant Science, Inc.
  • Robert I. Goldfarb, JD (COO) – Legal expert, formerly General Counsel at Andrx Corporation.
  • Evan Wasoff, CPA (CFO) – Financial expert with experience at Falcon Oil & Gas Ltd.

While experienced, the leadership team faces a serious uphill battle in reviving the company’s prospects.

What’s the Latest With Nexien?

  • Last Major Press Release? August 27, 2019. Since then—radio silence.
  • Ongoing R&D? Completely suspended due to financial constraints.
  • Investor Outlook? Uncertain, with stock volatility and no clear revenue model.

FAQs

Q: What does Nexien BioPharma do?
A: The company focuses on developing cannabinoid-based pharmaceuticals for medical conditions. However, due to financial struggles, all operations are currently at a standstill.

Q: Is NXEN stock a good investment?
A: Given its low cash reserves, halted R&D, and lack of revenue, Nexien is a high-risk penny stock. While the stock has seen gains, its long-term viability is questionable.

Q: Why is Nexien’s stock rising despite financial troubles?
A: The recent 150% increase in 2025 may be due to speculation, low float dynamics, or potential merger rumors. However, without solid fundamentals, the rally may not last.

Q: What’s next for Nexien?
A: The company is exploring mergers or restructuring to survive, but unless new capital is secured, the future remains bleak.

Final Verdict: Buy, Hold, or Avoid?

If you’re looking for a safe, growth-oriented investment, Nexien BioPharma isn’t it. The company is barely staying afloat, and its penny stock status makes it highly volatile. Unless they secure funding or a strong partner, Nexien is in deep trouble.

Speculative traders might find short-term opportunities.
Long-term investors should steer clear unless the company announces significant financial improvements.

Key Takeaways

  • Nexien’s stock price is $0.0140 as of March 14, 2025
  • The company has halted R&D and is struggling financially
  • A merger or restructuring is its best shot at survival
  • The stock has gained 150% in 2025 but remains highly risky

Investors should proceed with caution and conduct thorough due diligence before making any decisions.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.